| academic journal | Q737498 |
| scientific journal | Q5633421 |
| P6981 | ACNP journal ID | 3191410 |
| P8375 | Crossref journal ID | 267543 |
| P8903 | HAL journal ID | 145781 |
| P236 | ISSN | 2055-6837 |
| 2055-6845 | ||
| P7363 | ISSN-L | 2055-6837 |
| P1277 | JUFO ID | 85965 |
| P1055 | NLM Unique ID | 101669491 |
| P856 | official website | http://ehjcvp.oxfordjournals.org/content/ |
| P10283 | OpenAlex ID | V2735768669 |
| P3181 | OpenCitations bibliographic resource ID | 925234 |
| P7662 | Scilit journal ID | 1586256 |
| P1156 | Scopus source ID | 21100855908 |
| P495 | country of origin | United Kingdom | Q145 |
| P101 | field of work | cardiovascular pharmacotherapy | Q111763181 |
| P8875 | indexed in bibliographic review | Scopus | Q371467 |
| Science Citation Index Expanded | Q104047209 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cardiovascular pharmacotherapy | Q111763181 |
| P123 | publisher | Oxford University Press | Q217595 |
| P1476 | title | European heart journal. Cardiovascular pharmacotherapy |
| Q90185164 | "2019 GUIDELINES FOR THE DIAGNOSIS AND MANAGEMENT OF CHRONIC CORONARY SYNDROMES": CONGRATULATIONS AND TRIBULATIONS |
| Q90569456 | 2017 ESC guidelines focus on dual antiplatelet therapy |
| Q97536181 | 2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations |
| Q87716853 | A commentary on the new ESC guidelines on dyslipidaemias |
| Q92317285 | A gradient of benefit of beta-blockers in acute coronary syndrome patients: from severely depressed ejection fraction up to the normal level |
| Q37562899 | A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants |
| Q88146139 | A novel approach indirectly comparing benefit-risk balance across anti-thrombotic therapies in patients with atrial fibrillation |
| Q90569393 | A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation |
| Q36988873 | A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease |
| Q96432768 | A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers |
| Q101147155 | A tale of two therapies lipid-lowering vs anti-inflammatory therapy - a false dichotomy? |
| Q88146120 | A translational viewpoint explaining its potential salutary effects |
| Q54308036 | A way forward to the elimination of conflict of interest for experts involved in regulatory medicine and guidelines. |
| Q92674673 | ALGORITHM FOR THE MANAGEMENT OF ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: AN UPDATED PROPOSAL BASED ON EFFICACY CONSIDERATIONS |
| Q39482804 | Adherence to agents acting on the renin-angiotensin system in secondary prevention of non-fatal myocardial infarction: a self-controlled case-series study |
| Q90878055 | Adherence to dabigatran etexilate in atrial fibrillation patients intended to undergo electrical cardioversion |
| Q89022097 | Adherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real life. Results of the REAL-TICA registry |
| Q47966650 | Adherence to guidelines and registry data |
| Q95269070 | Adherence to guidelines, compliance to treatment, and treatment quality |
| Q96769719 | Adherence to prescribed medications in patients with heart failure - insights from liquid chromatography-tandem mass spectrometry-based urine analysis |
| Q92318414 | Adherence to statin therapy favours survival of patients with symptomatic peripheral artery disease |
| Q40351360 | Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists |
| Q39254947 | Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review. |
| Q38958862 | Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors |
| Q91681900 | After a long time, the new ESC Guidelines for the management of patients with supraventricular tachycardia are here |
| Q94581352 | Alirocumab and evolocumab: an indirect comparison of cardiovascular benefits |
| Q96693828 | All About Clinical Trial Course: One of the Masterpieces of the European Society of Cardiology - Working Group on Cardiovascular Pharmacotherapy Educational Programme |
| Q89743306 | All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease |
| Q91486998 | An observational study of INR control according to NICE criteria in patients with non-valvular atrial fibrillation-The SAIL Warfarin Out of Range Descriptors Study (SWORDS) |
| Q91277253 | Angiotensin receptor neprilysin inhibition for the treatment of hypertension: the neglected child in cardiovascular pharmacotherapy |
| Q26741084 | Angiotensin receptor neprilysin inhibitor LCZ696: a novel targeted therapy for arterial hypertension? |
| Q49617383 | Annual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration Adverse Event Reporting System |
| Q51317019 | Annual report of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. |
| Q92438729 | Anti-thrombotic strategies in elderly patients receiving platelet inhibitors |
| Q94466952 | Anticoagulation in COVID-19 |
| Q89470724 | Anticoagulation, atherosclerosis, and heart failure |
| Q96163251 | Antihypertensive drugs in COVID-19 infection |
| Q100732809 | Antiplatelet therapy after coronary bypass grafting: which regimen and for whom? |
| Q92834638 | Antiplatelet treatment in acute coronary syndrome. Still an issue |
| Q49552906 | Antithrombotic Therapy Use and Clinical Outcomes Following Thromboembolic Events in Patients with Atrial Fibrillation: Insights from ARISTOTLE. |
| Q103811663 | Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI |
| Q50068546 | Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention |
| Q92488707 | Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaborat |
| Q90026627 | Antithrombotic therapy for elderly patients with acute coronary syndrome: reasons to be cautious |
| Q90340963 | Antithrombotic therapy for lower extremity artery disease: is more intense therapy required? |
| Q89675782 | Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a Joint Position Paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with |
| Q92215710 | Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis |
| Q91629091 | Antithrombotic treatment and major adverse cardiac events after bleeding in patients with myocardial infarction: a retrospective analysis of nationwide registry data |
| Q96342266 | Aspirin adherence in subjects with glucose-6-phosphate-dehydrogenase deficiency having an acute coronary syndrome |
| Q88144554 | Aspirin and proton-pump inhibitors: interpreting the interplay |
| Q90026605 | Aspirin in Primary Prevention of Cardiovascular Disease in the Elderly |
| Q55266146 | Aspirin wears smart. |
| Q129191055 | Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial |
| Q90029803 | Aspirin-omitted dual antithrombotic therapy in nonvalvular atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention: results of a meta-analysis |
| Q96137708 | Aspirin-omitted dual antithrombotics versus triple antithrombotics: a trial sequential analysis |
| Q92438685 | Assessing Major Bleeding Risk in Atrial Fibrillation Patients Concurrently Taking Non-Vitamin K Antagonist Oral Anticoagulants and Antiepileptic Drugs |
| Q96342271 | Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor based approach |
| Q26740171 | Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion |
| Q91536261 | Association Between Serum Potassium Levels and Short-Term Mortality in Patients With Atrial Fibrillation or Flutter Co-treated With Diuretics and Rate- or Rhythm-Controlling Drugs |
| Q92003691 | Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study |
| Q96342294 | Association between renin-angiotensin system inhibitors and COVID-19 complications |
| Q91006478 | Association of Preceding Antithrombotic Therapy in Atrial Fibrillation Patients With Ischemic Stroke, Intracranial Hemorrhage, or Gastrointestinal Bleed and Mortality |
| Q88145498 | Atrial fibrillation and its complications: a focus on identifying risk factors and risk stratification |
| Q104581771 | Atrial fibrillation in registries |
| Q100381485 | Author's reply: Letter to the Editor in Response to Akita et al 2020 |
| Q48650333 | Back to the future: the crucial role of clinical registries in the era of randomized controlled trials for identifying the optimal medical therapy of heart failure |
| Q91682729 | Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review |
| Q130045593 | Beta-adrenergic blockade increases pulmonary vascular resistance and causes exaggerated hypoxic pulmonary vasoconstriction at high altitude: a physiological study |
| Q98611739 | Beta-blocker therapy after myocardial infarction guided by left ventricular ejection fraction: is 50 the new 40? |
| Q57189971 | Beware of early drug intolerance in secondary prevention of cardiovascular disease |
| Q92743880 | Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis |
| Q90588122 | Breaking the rules for studies using real-world observational data: The case of direct-acting anticoagulants and antiepileptic drugs |
| Q93367065 | CABANA trial: disappointing results? |
| Q94606319 | CHOICES IN ANTITHROMBOTIC MANAGEMENT FOR PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION. QUESTIONS (AND ANSWERS) IN CHRONOLOGICAL SEQUENCE |
| Q97555691 | COVID-19: how things change in a while |
| Q97551341 | Can we offer tailor-made pharmacological treatment of patients with acute coronary syndrome? |
| Q97435276 | Cancer treatment and atrial fibrillation: use of pharmacovigilance databases to detect cardiotoxicity |
| Q94604288 | Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management |
| Q88146201 | Cardio-renal protection through renin-angiotensin-aldosterone system inhibition: current knowledge and new perspectives |
| Q53561964 | Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats. |
| Q100381506 | Cardiorenal protection of Sodium-glucose cotransporter 2 inhibitors beyond Diabetes. News from the European Society of Cardiology Congress 2020 |
| Q97596368 | Cardiovascular Pharmacotherapy in Older People - Challenges Posed by Cardiovascular Drug Prescription in the Elderly |
| Q88146207 | Cardiovascular Pharmacotherapy is moving! |
| Q48650343 | Cardiovascular pharmacology: a look back and a glimpse into the future |
| Q50120473 | Cardiovascular pharmacotherapy |
| Q88097694 | Cardiovascular pharmacotherapy and real-world data |
| Q88283707 | Cardiovascular pharmacotherapy-2015 was a good year |
| Q90155553 | Cardiovascular pharmacotherapy: a new ESC Handbook comprehensively addresses pharmacological treatment issues for patients with cardiovascular disease |
| Q26741082 | Cardiovascular safety of anti-diabetic drugs |
| Q88146115 | Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology |
| Q52853892 | Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. |
| Q88145503 | Cenderitide: a multivalent designer-peptide-agonist of particulate guanylyl cyclase receptors with considerable therapeutic potential in cardiorenal disease states |
| Q36860608 | Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions |
| Q97551106 | Central Apnoeas and Ticagrelor Related Dyspnoea in Patients with Acute Coronary Syndrome |
| Q40280190 | Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry |
| Q96437584 | Changing paradigms in antiplatelet therapy after coronary intervention |
| Q50074489 | Changing paradigms in oral anticoagulation during cardioversion in Europe. |
| Q94456661 | Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety |
| Q130109637 | Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction |
| Q47549080 | Circadian variation of ticagrelor-induced platelet inhibition in healthy adulty |
| Q88146181 | Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial |
| Q91277255 | Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) |
| Q88146212 | Closing the information gap between clinical and postmarketing trials: the case of dabigatran |
| Q104058013 | Colchicine and Risk of Non-Cardiovascular Death in Patients with Coronary Artery Disease: a Pooled Analysis Underling Possible Safety Concerns |
| Q93243242 | Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks? |
| Q91801263 | Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes |
| Q97536151 | Combinations of Antithrombotic Therapies Prescribed after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndromes and Atrial Fibrillation: Data from the Nationwide MATADOR-PCI Registry |
| Q87918858 | Comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al |
| Q101324702 | Commentary regarding the article by Gragnano et al. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY |
| Q91508835 | Comments on: Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose |
| Q53966050 | Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study. |
| Q90003034 | Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system |
| Q92826996 | Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of 5 contemporary European registries |
| Q92674695 | Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study |
| Q90260371 | Comparison of dronedarone versus flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation - a systematic review and meta-analysis |
| Q38886540 | Congestive heart failure: More common as well as an important cardiovascular outcome |
| Q89314027 | Congestive heart failure: more common as well as an important cardiovascular outcome |
| Q89487960 | Congestive heart failure: more common as well as an important cardiovascular outcome: reply |
| Q50042165 | Consensus document on hypertension and cardiac arrhythmias |
| Q38388751 | Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study. |
| Q39482814 | Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations |
| Q88144552 | Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) |
| Q96163261 | Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality |
| Q87716857 | Coronary artery disease and arrhythmias |
| Q50575232 | Coronary artery disease severity and long-term cardiovascular risk in patients with myocardial infarction: a Danish nationwide register-based cohort study. |
| Q90026524 | Correspondence: Current opinion of the ESC Working Group on Cardiovascular Pharmacotherapy and ESC Council on Stroke |
| Q58606106 | Corrigendum |
| Q92152660 | Corrigendum to: Adherence to dabigatran etexilate in atrial fibrillation patients intended to undergo electrical cardioversion |
| Q88120546 | Corrigendum to: Annual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration Adverse Event Reporting System |
| Q89837225 | Corrigendum to: Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry |
| Q99548478 | Corrigendum to: Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Car |
| Q94584972 | Corrigendum to: Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients |
| Q57026586 | Corrigendum to: Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review |
| Q97435061 | Corrigendum: ESC position paper on statins adherence and implementation of new lipid-lowering medications: barriers to be overcome |
| Q50120478 | Cost-effectiveness with PCSK9 inhibitors: a matter of costs |
| Q97518234 | Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease |
| Q91549353 | Critical appraisal of the AUGUSTUS trial |
| Q90975806 | Critical appraisal of the COMPASS trial |
| Q104464894 | Cumulative evidence on DAPT: different strategies, heterogenous populations, complex decisions |
| Q48021754 | Danish trends in pharmacotherapy, comorbidities, and demographics in patients referred for coronary angiography: what changed during a decade? |
| Q91763256 | De-escalation of Antiplatelets After Percutaneous Coronary Intervention: A Bayesian Network Meta-Analysis of Various De-escalation Strategies |
| Q102129880 | Depressive symptoms and non-adherence to treatable cardiovascular risk factors' medications in the CONSTANCES cohort |
| Q49058595 | Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients |
| Q90636159 | Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations |
| Q38886447 | Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes |
| Q50571761 | Did referral patterns for coronary angiography change in Europe? What can we learn from Denmark? |
| Q90569376 | Differences in the risk of stroke, bleeding events, and mortality between female and male patients with atrial fibrillation during warfarin therapy |
| Q101058936 | Different left ventricular remodeling patterns and clinical outcomes between non-ischemic and ischemic etiologies in heart failure patients receiving sacubitril/valsartan treatment |
| Q91006013 | Differential Epigenetic Factors in the Prediction of Cardiovascular Risk in Diabetic Patients |
| Q100732816 | Differential effects of dual antiplatelet therapy in patients presented with acute coronary syndrome vs. stable ischaemic heart disease after coronary artery bypass grafting |
| Q90026575 | Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countries |
| Q89291913 | Digoxin: beneficial or harmful? |
| Q103010644 | Direct Oral Anticoagulants versus Vitamin K Antagonists for the treatment of Left Ventricular Thrombosis: a systematic review of the literature and meta-analysis |
| Q26741058 | Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel |
| Q104503656 | Double or triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: not a matter of faith |
| Q103034857 | Double vs. triple antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: does clinical presentation matter? |
| Q56979996 | Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute? |
| Q26741074 | Drug therapy in cardiac arrest: a review of the literature |
| Q26741055 | Dual antiplatelet therapy: optimal timing, management, and duration |
| Q91911491 | Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy |
| Q101147162 | Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug eluting stent implantation: a network Meta-analysis |
| Q101147141 | EFFECT oF STATIN THERAPY oN SARS-CoV-2 INFECTION-RELATED |
| Q88146129 | EHJ - Cardiovascular Pharmacotherapy: a warm welcome to the new member of the ESC journal family |
| Q90569461 | ESC 2017 STEMI Guidelines: a step forward for a better cure |
| Q91234685 | ESC Council on hypertension position document on the management of hypertensive emergencies |
| Q92595780 | ESC Guidelines revisited |
| Q88146146 | ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry |
| Q92232191 | ESC position paper on statins adherence and implementation of new lipid-lowering medications: barriers to be overcome |
| Q96962198 | Early glycemic changes after initiation of oral anti-diabetic medication and risk of major adverse cardiovascular events: results from a large primary care population of patients with type 2 diabetes |
| Q88916650 | Early occurrence of drug intolerance as risk factor during follow-up in patients with acute coronary syndrome or coronary revascularization |
| Q88146143 | Editorial Comment for the "Risk of Thrombocytopenia with Glycoprotein IIb/IIIa Inhibitors across Drugs and Patient Populations: a Meta-Analysis of 29 Large Placebo-Controlled Randomized Trials". Thrombocytopenia as an important complication with the |
| Q53777211 | Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for pati |
| Q54375523 | Editorial on PEGASUS-TIMI 54. |
| Q98459742 | Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: One year follow up of the prospective observational ETNA-AF-Europe study |
| Q100508934 | Effect of Ticagrelor Monotherapy on Mortality After PCI: A Systematic Review and Meta-Analysis of Randomized Trials Including 26143 patients |
| Q96834601 | Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side-effects: a randomized, double blinded crossover trial |
| Q91913634 | Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction |
| Q39481514 | Effect of inter-individual blood pressure variability on the progression of atherosclerosis in carotid and coronary arteries: a post hoc analysis of the NORMALISE and PREVENT studies |
| Q61821140 | Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis |
| Q47704546 | Effect of rapid desensitization on platelet inhibition and basophil activation in patients with aspirin hypersensitivity and coronary disease. |
| Q100429862 | Effectiveness and Safety of Oral Anticoagulants Among Non-Valvular Atrial FibrillationPatients with Polypharmacy |
| Q91487006 | Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish nationwide cohort |
| Q64123555 | Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1 |
| Q90246563 | Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease |
| Q27023041 | Effectiveness of colchicine for the prevention of recurrent pericarditis and post-pericardiotomy syndrome: an updated meta-analysis of randomized clinical data |
| Q129319897 | Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial |
| Q88145821 | Effects of digitalis on mortality in a large cohort of implantable cardioverter defibrillator recipients: results of a long-term follow-up study in 1020 patients |
| Q104789339 | Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study |
| Q124851240 | Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials |
| Q129793312 | Effects of sodium-glucose co-transporter 2 inhibitors on heart failure events in chronic kidney disease: a systematic review and meta-analysis |
| Q91116598 | Efficacy and Safety of Edoxaban Compared to Warfarin According to the Burden of Diseases in Patients with Atrial Fibrillation: Insights from the ENGAGE AF-TIMI 48 |
| Q96579652 | Efficacy and safety of direct oral anticoagulants versus low molecular weight heparin for cancer related venous thromboembolism: A meta-analysis of randomized trials |
| Q101567526 | Efficacy and safety of early initiation of eplerenone treatment in patients with acute heart failure (EARLIER trial): a multicenter, randomized, double-blind, placebo-controlled trial |
| Q53581195 | Efficacy and safety of prolonged dual antiplatelet therapy: a meta-analysis of 15 randomized trials enrolling 85 265 patients. |
| Q92890427 | Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54 |
| Q88146156 | End of story? Studies on prevention of reperfusion injury encounter perpetual defeats |
| Q95524567 | Erratum |
| Q88612667 | Erratum to: SGLT1 does compensate for SGLT2 inhibition |
| Q88146168 | European Heart Journal - CVP: what is next? |
| Q90155556 | European Heart Journal - Cardiovascular Pharmacotherapy has received its first Impact Factor of 6.723 |
| Q88146126 | European Heart Journal - Cardiovascular Pharmacotherapy: a new journal within the European Heart Journal family |
| Q92385291 | European Heart Journal - Cardiovascular Pharmacotherapy: now accepted for an official Impact Factor |
| Q48714148 | European Heart Journal-Cardiovascular Pharmacotherapy in 2016: entering a new level of international recognition |
| Q88146136 | European Society of Cardiology Working Group on Cardiovascular Pharmacology and Drug Therapy. The chairman's report at the general assembly 2014 |
| Q90767595 | Evidence beyond the digital medication pill |
| Q52803316 | Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with RAAS-inhibitors - Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. |
| Q88143611 | Exploring the potential of low-dose sulfasalazine in stable coronary artery disease patients: randomized, double-blind, placebo-controlled study |
| Q92646913 | External applicability of the COMPASS trial: the Western Denmark Heart Registry |
| Q114009838 | Fast vs. ultraslow thrombolytic infusion regimens in patients with obstructive mechanical prosthetic valve thrombosis: a pilot randomized clinical trial |
| Q130029714 | Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study |
| Q102072481 | Focus on blood pressure and risk factor intervention |
| Q92466769 | Focus on pharma in acute coronary syndrome |
| Q94929795 | Focus on subpopulations of atrial fibrillation patients |
| Q26741078 | From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications |
| Q48021946 | Gastrointestinal haemorrhage in atrial fibrillation patients: impact of quality of anticoagulation control. |
| Q39193538 | Gender differences in the effects of cardiovascular drugs |
| Q87918778 | Geographical differences in prescription of secondary preventive drug therapy after acute myocardial infarction in Norway |
| Q26741067 | Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease |
| Q93059318 | Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction |
| Q88143614 | Glycemic control and acute coronary syndrome: the debate continues |
| Q90806254 | Head-to-head comparison between the non-vitamin K antagonist oral anticoagulants for treatment of venous thrombo-embolism: do we really need it? |
| Q87909621 | Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction |
| Q94539588 | Hematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants |
| Q104581744 | Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial |
| Q92565201 | High burden of drug therapy in adult congenital heart disease: polypharmacy as marker of morbidity and mortality |
| Q90188962 | High-intensity lipid lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality |
| Q51317046 | Highlights from the 65th American College of Cardiology Annual Scientific Session (ACC 2016). |
| Q54427284 | How European Society of Cardiology guidelines are made. |
| Q55263543 | How does the TRS 2°P score relate to real-world patients? |
| Q92239458 | How to implement the recommendations of the 2018 ESC/ESH Hypertension Guidelines in a given patient: a step by step approach |
| Q53609113 | Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. |
| Q47876951 | Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), |
| Q128505560 | Hypertension in pregnancy—what's new in the 2023 ESH Guidelines for the management of arterial hypertension |
| Q94468906 | Identification of anticancer drugs associated with atrial fibrillation - analysis of the WHO pharmacovigilance database |
| Q90029757 | Impact of Liver Disease on Oral Anticoagulant Prescription and Major Adverse Events in Patients with Atrial Fibrillation |
| Q90587979 | Impact of Reduced-Dose Prasugrel vs. Standard-Dose Clopidogrel on In-Hospital Outcomes of Percutaneous Coronary Intervention in 62,737 Patients with Acute Coronary Syndromes: A Nationwide Registry Study in Japan |
| Q91919211 | Impact of Vitamin D on Cardiac structure and function in CKD patients with hypovitaminosis D, a randomised controlled trial and meta-analysis |
| Q99589571 | Impact of White Blood Cell Count on Clinical Outcomes in Patients Treated with Aspirin-Free Ticagrelor Monotherapy after Percutaneous Coronary Intervention: Insights from the GLOBAL LEADERS Trial |
| Q91763230 | Impact of angiotensin receptor blockers on mortality after hospitalization for symptomatic lower extremity artery disease |
| Q92250440 | Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial |
| Q98170836 | Impact of opioids on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial |
| Q38830472 | Impact of renal impairment on platelet reactivity and clinical outcomes during chronic dual antiplatelet therapy following coronary stenting |
| Q89636645 | Importance of post-approval real-word evidence |
| Q91806475 | Indirect Comparison of the Efficacy and Safety of Alirocumab and Evolocumab: A Systematic Review and Network Meta-Analysis |
| Q90909420 | Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the |
| Q39118038 | Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes |
| Q97518270 | Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19 in critically ill elderly patients |
| Q98775269 | Intensive blood pressure control appears to be effective and safe in patients with peripheral artery disease: The Systolic Blood Pressure Intervention Trial (SPRINT) |
| Q90139847 | Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial |
| Q98156946 | Intensive versus standard blood pressure control and vascular procedures: Insights from the Systolic Blood Pressure Intervention Trial (SPRINT) |
| Q39386445 | Interleukin-1 Blockade for the Treatment of Pericarditis |
| Q26822876 | Iron deficiency in patients with heart failure |
| Q91111265 | Is P2Y12 inhibitor therapy associated with an increased risk of cancer? |
| Q95330761 | Is the answer to clinical questions provided by Bayesian network meta-analysis? Regarding the optimal duration of DAPT and the best subsequent SAPT |
| Q28078709 | Is the use of renin-angiotensin system inhibitors in patients with aortic valve stenosis safe and of prognostic benefit? A systematic review and meta-analysis |
| Q88651655 | Is there a 'therapeutic window' for antiplatelet therapy? |
| Q89781597 | Is ticagrelor safe in octogenarian patients with non-ST elevation acute coronary syndromes? |
| Q91329756 | Ivabradine for heart failure: regulatory differences in Europe and United States |
| Q100407028 | LATEST NEWS ON HEART FAILURE AND ATRIAL FIBRILLATION FROM THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2020 |
| Q96617265 | Left Ventricular Thrombosis: New Perspectives on an Old Problem |
| Q100381507 | Letter to the editor in response to Akita et al 2020 |
| Q129242930 | Letter to the editor: 1-year clinical outcomes of bivalirudin vs. unfractionated heparin in patients with type 2 diabetes undergoing elective percutaneous coronary intervention |
| Q92521816 | Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology |
| Q90353805 | Lipids and antithrombotic treatment |
| Q58606700 | Long term antiarrhythmic drug treatment after atrial fibrillation ablation: does too obstinate rhythm control strategy bring serious risk of proarrhythmia to ablated patients? |
| Q91913710 | Long-Term Prognosis of De-Novo Atrial Fibrillation during Acute Myocardial Infarction - The Impact of Anti-Thrombotic Treatment Strategies |
| Q93176431 | Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk |
| Q88351152 | Loop diuretics for chronic heart failure: a foe in disguise of a friend? |
| Q89715333 | Low Adherence to Statin Treatment during the First Year after an Acute Myocardial Infarction is associated with Increased Second Year Mortality Risk- An Inverse Probability of Treatment Weighted Study on 54,872 Patients |
| Q90006221 | Low-quality of some generic medicinal products represents a matter for growing concern |
| Q96962224 | MSc in Clinical Trials - A New Flagship Working Group Project |
| Q57628424 | Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report |
| Q94468989 | Management of patients with combined arterial hypertension and aortic valve stenosis: a consensus document from the Council on Hypertension and Council on Valvular Heart Disease of the European Society of Cardiology, the European Association of Card |
| Q101403981 | Management of pregnancy-related hypertensive disorders in patients infected with SARS CoV-2: pharmacological and clinical issues |
| Q53649936 | Mangafodipir as a cardioprotective adjunct to reperfusion therapy: a feasibility study in patients with ST-segment elevation myocardial infarction. |
| Q47561303 | Market licensing of type 2 diabetes medicinal products based on patient-relevant hard outcomes: is there hope? |
| Q61671207 | Medical management: the dark side of acute coronary syndromes |
| Q64265319 | Medical misinformation: vet the message! |
| Q99720144 | Medication in adults after atrial switch for transposition of the great arteries: clinical practice and recommendations |
| Q28077901 | Melatonin has multiorgan effects |
| Q91634059 | Meta-Analysis of Studies Examining the External Validity of the DAPT Score |
| Q38929573 | Meta-analysis of admission hyperglycaemia in acute myocardial infarction patients treated with primary angioplasty: a cause or a marker of mortality? |
| Q50235296 | Metabolic control, anticoagulation, and gender aspects |
| Q95305555 | Methodological Considerations for Investigating Oral Anticoagulation Persistence in Atrial Fibrillation |
| Q91894131 | Might renin-angiotensin system blockers play a role in the COVID-19 pandemic? |
| Q26741152 | Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives |
| Q99548480 | Minimizing bleeding events |
| Q38690757 | Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting |
| Q91331367 | Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System |
| Q39481501 | NSAIDs are associated with increased risk of atrial fibrillation in patients with prior myocardial infarction: a nationwide study |
| Q57026590 | Neoatherosclerosis after drug-eluting stent implantation: a novel clinical and therapeutic challenge |
| Q91855833 | Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients |
| Q91844430 | New AI Prediction Model Using Serial PT-INR Measurements in AF Patients on VKAs: GARFIELD-AF |
| Q53609119 | New ESC/EACTS Guidelines for the management of atrial fibrillation. |
| Q46072608 | New Strategies for the Development of Lipid Lowering Therapies to Reduce Cardiovascular Risk |
| Q129736323 | New data on NOVEL ORAL ANTICOAGULANT, SGLT2i, lipid treatment and genetics |
| Q104582036 | New evidence from the scientific sessions 2020 of the American Heart Association |
| Q90569471 | New input on antiplatelet treatment and registry studies |
| Q38930008 | New oral anticoagulants: a practical guide for physicians |
| Q89456979 | New potassium binders reduce the risk of hyperkalaemia in patients treated with renin-angiotensin-aldosterone system inhibitors |
| Q88145820 | News from EHJCVP |
| Q91505357 | Non-Vitamin K Antagonist Oral Anticoagulants and Warfarin in Atrial Fibrillation Patients with Concomitant Peripheral Artery Disease |
| Q28969131 | Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case–time–control study |
| Q88146191 | Non-steroidal anti-inflammatory drugs and incident atrial fibrillation |
| Q88146243 | Non-steroidal anti-inflammatory drugs and incident atrial fibrillation |
| Q47918560 | Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis |
| Q28067412 | Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future : Views from a workshop at the European Medicines Agency (EMA) |
| Q89874548 | Obesity and Atrial Fibrillation: Making inroads through fat |
| Q98775284 | Off-label use of reduced dose direct oral factor Xa-inhibitors in subjects with atrial fibrillation: a review of clinical evidence |
| Q90919562 | Old and new drugs in cardiovascular pharmacotherapy |
| Q98657614 | Optimal P2Y12 inhibition in older adults with acute coronary syndromes: A network meta-analysis of randomized controlled trials |
| Q39481491 | Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival. |
| Q92231059 | Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council |
| Q93036065 | Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study |
| Q97529794 | Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis |
| Q26741051 | Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease |
| Q90070181 | P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects |
| Q96437535 | P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients |
| Q38830465 | P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries |
| Q93005129 | PCSK9 and inflammation: a review of experimental and clinical evidence |
| Q99561743 | PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY |
| Q98226725 | Patient-Reported Outcomes and Medication Adherence in Patients with Heart Failure |
| Q48255595 | Patients with atrial fibrillation and diabetes: does apixaban remain the drug of choice? |
| Q100663052 | Patients with diabetes mellitus and atrial fibrillation treated with NOACs: Meta-analysis of 8 outcomes in 58, 634 patients across 4 randomized controlled trials |
| Q92003666 | Peripartum management of hypertension. A position paper of the ESC Council on Hypertension and the European Society of Hypertension |
| Q90569467 | Peripheral arterial disease and limb salvage: a new arena for the cardiologist |
| Q26740181 | Periprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventions |
| Q90650031 | Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing PCI: a randomized controlled clinical trial |
| Q90026615 | Pharmacogenomic Polygenic Response Score Predicts Ischemic Events and Cardiovascular Mortality in Clopidogrel-Treated Patients |
| Q26991627 | Pharmacotherapy for coronary microvascular dysfunction |
| Q88146132 | Pharmacotherapy in heart failure with reduced ejection fraction during the last 20 years, and the way ahead for precision medicine |
| Q100756256 | Pharmapulse Report about CAD/Valvular Disease ESC Meeting 2020 |
| Q39000038 | Plaque imaging to refine indications for emerging lipid-lowering drugs |
| Q91250716 | Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study |
| Q92762181 | Potassium homeostasis in patients with atrial fibrillation |
| Q45040463 | Potassium levels in acute myocardial infarction: definitely worth paying attention to. |
| Q49922766 | Potential benefits of prasugrel and ticagrelor is diabetics are not substantiated by the Food and Drug Administration adverse event repository |
| Q99561715 | Potentially Inappropriate Prescriptions in Heart Failure with Reduced Ejection Fraction (PIP-HFrEF) |
| Q92907727 | Practical Guidance for P2Y12 Inhibitors in Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention |
| Q88146205 | Practical advice on safe and effective use of non-vitamin K antagonist oral anticoagulants |
| Q97551051 | Pragmatic approaches to the next generation of clinical trials in heart failure |
| Q92178551 | Prasugrel vs. ticagrelor after acute coronary syndrome: a critical appraisal of the ISAR-REACT 5 trial |
| Q52661111 | Preadmission Use of Platelet Inhibitors and Short-Term Stroke Mortality:A Population-Based Cohort Study. |
| Q97550992 | Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters |
| Q96693838 | Prescriber responsibility, predictors for initiation, and 20-year trends in use of non-aspirin non-steroidal anti-inflammatory drugs in patients with cardiovascular contraindications: a nationwide cohort study |
| Q91183789 | Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes - a survey of cardiologists' attitudes and practice |
| Q88144559 | Promoting high-density lipoprotein function via intravenous infusion: the rebirth of apoA-I Milano? |
| Q96580098 | Protective association of angiotensin blockade with influenza: A result of immortal time bias? |
| Q39482145 | Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events |
| Q100429873 | REDUCE-IT INTERIM: Accumulation of Data Across Prespecified Interim Analyses to Final Results |
| Q48628910 | Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study |
| Q91121181 | Rationale, Experimental Data, and Emerging Clinical Evidence on Early and Preventive Use of Levosimendan in Patients with Ventricular Dysfunction |
| Q38999087 | Real world insights on the initiation and treatment duration of oral antiplatelets in acute coronary syndromes: a retrospective cohort study. |
| Q90899316 | Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review |
| Q50665549 | Recent developments in the science of proarrhythmic cardiac safety of new drugs. |
| Q90767520 | Recommendations and levels of evidence in the guidelines of the European Society of Cardiology: current scenario and time trends |
| Q92058713 | Relationship between degree of heparin anticoagulation and clinical outcome in patients receiving potent P2Y12-inhibitors with no planned glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention in acute myocardial infarction: a VAL |
| Q50105402 | Relationship of loop diuretic use with exercise intolerance in heart failure with preserved ejection fraction |
| Q54533325 | Renal denervation: back to reality, finally! |
| Q88146160 | Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in patients with resistant hypertension to improve patients' adherence |
| Q104498655 | Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes fromCoViD-19: systematic review and meta-analysis |
| Q91508774 | Reply letter to Jutta Heinrich-Nols's and Joanne van Ryn's response to: Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose |
| Q90621774 | Resistant hypertension: new insights and therapeutic perspectives |
| Q88144381 | Response to comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al |
| Q90588017 | Response to the "Breaking the rules for studies using real-world observational data: The case of direct acting anticoagulants and antiepileptic drugs by Dr. Brown et al." |
| Q87919207 | Response to the 'Comment on the editorial by Turner et al. on Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.' |
| Q93193980 | Response to: Antithrombotic therapy for elderly patients with acute coronary syndrome: reasons to be cautious |
| Q90026766 | Response to: Current opinion of the ESC Working Group on Cardiovascular Pharmacotherapy and ESC Council on Stroke |
| Q94466931 | Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan) |
| Q88145501 | Rise and fall of dronedarone: the need for new drugs |
| Q51280337 | Risk factor changes and incident atrial fibrillation among middle-aged men in the Malmö Preventive Project cohort. |
| Q98156898 | Risk of Fracture in Patients with Nonvalvular Atrial Fibrillation Initiating Direct Oral Anticoagulants vs Vitamin K Antagonists |
| Q91335545 | Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study |
| Q96617313 | Risk of infections in patients treated with ticagrelor versus clopidogrel: a systematic review and meta-analysis |
| Q33434702 | Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials |
| Q88146118 | SGLT1 does compensate for SGLT2 inhibition |
| Q94530528 | Sacubitril/valsartan in COVID-19 patients: the need for trials |
| Q57260244 | Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study |
| Q101058818 | Safety and efficacy of double versus triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of NOAC-based randomized cli |
| Q91919257 | Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation |
| Q88144548 | Second year of a journal |
| Q26740185 | Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection |
| Q36988862 | Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction |
| Q92385193 | Should we consider early de-escalation of maintenance dose of antiplatelet therapy post-ACS? |
| Q53809147 | Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score. |
| Q95730284 | Smoking and Outcomes Following Guided De-escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients: A Substudy from the Randomized TROPICAL-ACS Trial |
| Q89876387 | Smoking and antiplatelet therapy after acute coronary syndromes |
| Q28072765 | Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects |
| Q90820046 | Speculation is not evidence: antihypertensive therapy and COVID-19 |
| Q54646976 | Starting up a new Journal within the European Heart Journal Family. |
| Q94604307 | Statin therapy and SAR-COV-2: an available and potential therapy? |
| Q94456666 | Statin therapy in COVID-19 infection |
| Q96305608 | Statin therapy in COVID-19 infection: much more than a single pathway |
| Q88146172 | Stroke prevention in atrial fibrillation: changing concepts |
| Q91294624 | Switching from Vitamin K Antagonist to Dabigatran in Atrial Fibrillation: Differences According to Dose |
| Q88146239 | Synergistic effects of cardiac resynchronization therapy and drug up-titration in heart failure: is this enough? |
| Q97551034 | Systemic fibrinolysis for acute pulmonary embolism complicating acute respiratory distress syndrome in severe COVID-19: a case series |
| Q94659477 | THE INTERPLAY BETWEEN CARDIOLOGY AND DIABETOLOGY: A RENEWED COLLABORATION TO OPTIMIZE CARDIOVASCULAR PREVENTION AND HEART FAILURE MANAGEMENT |
| Q26740179 | Targeting T cells to treat atherosclerosis: odyssey from bench to bedside |
| Q38782804 | Temporal trends in acute myocardial infarction presentation and association with use of cardioprotective drugs: A nationwide registry-based study |
| Q48506523 | The 2016 version of the European Guidelines on Cardiovascular Prevention |
| Q89470731 | The Heart Failure Association Congress confirms itself as the largest European Society of Cardiology sub-speciality congress |
| Q99561723 | The Perils of Data Sharing, Meta-analyses, and Estimating Rosiglitazone Cardiovascular Risk |
| Q98170834 | The Use of Novel Oral Anti-Coagulant's (NOAC) compared to Vitamin K Antagonists (Warfarin) in patients with Left Ventricular thrombus after Acute Myocardial Infarction (AMI) |
| Q89743308 | The Use of Superlatives in News Articles Covering Cardiovascular Drugs |
| Q91824185 | The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials |
| Q101147180 | The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials |
| Q88283706 | The application to MEDLINE from European Heart Journal-Cardiovascular Pharmacotherapy has been accepted! |
| Q98241923 | The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study |
| Q101058822 | The burden of cholesterol accumulation through the lifespan: why pharmacological intervention should start earlier to go further? |
| Q26741071 | The current role and future prospects of D-dimer biomarker |
| Q36860614 | The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014. |
| Q93176409 | The importance of adherence and persistence with oral anticoagulation treatment in patients with atrial fibrillation |
| Q91603634 | The management of stress hyperglycaemia in patients experiencing acute coronary syndrome: a topic worth revisiting |
| Q95943779 | The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system |
| Q104503653 | The multiplication of loaves and fishes approach: A Critic to Double anti-thrombotics or to Double number of ischemic events? |
| Q51411850 | The quality of warfarin therapy and CHA2DS2-VASc score associate with the incidence of myocardial infarction and cardiovascular outcome in patients with atrial fibrillation. Data from the nationwide FinWAF registry. |
| Q92548167 | The relevance of depressive symptoms for the outcome of patients receiving vitamin K-antagonists: Results from the thrombEVAL cohort study |
| Q26741061 | The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent |
| Q94561291 | The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19 |
| Q39061640 | Thiazolidinediones are associated with a decreased risk of atrial fibrillation compared with other antidiabetic treatment: a nationwide cohort study |
| Q89464928 | Thromboembolism and bleeding complications in anticoagulated patients with atrial fibrillation and native aortic or mitral valvular heart disease: A descriptive nationwide cohort study |
| Q98199903 | Ticagrelor and The Risk of Staphylococcus Aureus Bacteremia and Other Infections |
| Q91820834 | Ticagrelor in patients with myocardial infarction: is the treatment strategy crystal clear? |
| Q47241271 | Time to epinephrine and survival after paediatric out-of-hospital cardiac arrest |
| Q95305633 | Time to treatment still matters in ST-elevation myocardial infarction: a call to maintain treatment effectiveness during the COVID-19 pandemic |
| Q28078430 | Treating arrhythmias with adjunctive magnesium: identifying future research directions |
| Q57630432 | Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA2DS2-VASc score |
| Q50211580 | Trends in Optimal Medical Therapy Prescription and Mortality After Admission for Acute Coronary Syndrome: a 9-Year Experience in a Real-World Setting |
| Q90804966 | Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry |
| Q88097689 | Trimetazidine: is there a role beyond angina? |
| Q39193524 | Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a viewpoint |
| Q88145494 | Unobserved automated office blood pressure measurement in the Systolic Blood Pressure Intervention Trial (SPRINT): systolic blood pressure treatment target remains below 140 mmHg |
| Q101567599 | Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention |
| Q92385287 | Unsolved issues in oral anticoagulation treatment in atrial fibrillation |
| Q88145491 | Update from EHJ CVP |
| Q39481709 | Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries |
| Q92397624 | VTE and anti-coagulation therapy in cancer patients |
| Q39481520 | Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. |
| Q91142282 | Vascular Ehlers-Danlos syndrome: Can the beneficial effect of celiprolol be extrapolated to bisoprolol? |
| Q92674664 | Very Short vs. Long Dual Antiplatelet Therapy after Second Generation Drug-eluting Stents in 35,785 Patients undergoing Percutaneous Coronary Interventions: a Meta-analysis of Randomised Controlled Trials |
| Q53116570 | Visit-to-visit blood pressure variability: an epiphenomenon or a risk for the progression of carotid artery remodelling: reply. |
| Q89314031 | Visit-to-visit blood pressure variability: an epiphenomenon or a risk for the progression of carotid artery remodelling? |
| Q91006023 | Vitamin K Antagonists versus Direct Oral Anticoagulants After Transcatheter Aortic Valve Implantation in Atrial Fibrillation |
| Q91595820 | What are the pharmacodynamics of loop diuretics? |
| Q104617554 | What is linking COVID-19 and endothelial dysfunction? Updates on nanomedicine and bioengineering from the 2020 AHA Scientific Sessions |
| Q54356355 | What is the need for another new journal? |
| Q88178751 | With regard to the paper by Zannad et al. entitled Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment versus risk aversion |
| Q89908698 | With regard to the papers by Kumar et al. and de Leeuw and de Boer addressing the cardiovascular safety and efficacy of anti-diabetic drugs |
| Q89636635 | Worldwide reporting of fatal outcomes after ticagrelor to the US Food and Drug Administration |
| Category:European Heart Journal | wikimedia |
Search more.